Results 111 to 120 of about 33,791,512 (292)

Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement

, 2018
Francesco Giorgino,1 Alfred Penfornis,2 Valeria Pechtner,3 Raffaella Gentilella,4 Antonella Corcos4 1Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology, and Metabolic Diseases, University of Bari ...
Corcos A, Penfornis A, Pechtner V, Giorgino F, Gentilella R   +4 more
core  

Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas

, 2011
Glucagon-like peptide-1 (GLP-1) receptor imaging is superior to somatostatin receptor subtype 2 (sst(2)) imaging in localizing benign insulinomas. Here, the role of GLP-1 and sst(2) receptor imaging in the management of malignant insulinoma patients was ...
Bomanji, Jamshed, Kurzawinski, Tom R, Ell, Peter J., Caplin, Martyn E, Damian Wild, Peter J. Ell, Flavio Forrer, Tom R. Kurzawinski, Jamshed Bomanji, Emanuel Christ, Christ, Emanuel, Weber, Wolfgang A., Aurel Perren, Jean Claude Reubi, Weber, Wolfgang A, Michael Brändle, Perren, Aurel, Martyn E. Caplin, Caplin, Martyn E., Seufert, Jochen, Forrer, Flavio, Ell, Peter J, Reubi, Jean Claude, Brändle, Michael, Wolfgang A. Weber, Kurzawinski, Tom R., Wild, Damian, Jochen Seufert   +27 more
core   +1 more source

Urogenital Infection Risk Associated With SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Target Trial Emulation

Clinical Pharmacology &Therapeutics, EarlyView.
Although sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are recommended for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), concerns regarding urogenital infections persist. Therefore, we evaluated the risk of urinary tract infection (UTI) and genital tract infection (GTI) after SGLT2i initiation in this population ...
Young‐Mi Ah, Junsung Nam, Jung Wook Youn, Yun Mi Yu, Soyoung Kang   +4 more
wiley   +1 more source

Ülseratif kolitli hastalarda 'glucagon like peptide-1' ve 'glucagon like peptide-2' düzeyleri

, 2013
Giriş-Amaç: Ülseratif kolit hastalığı barsağın kronik inflamatuvar bir hastalığıdır. ?Glucagon like peptide-1? barsak enteroendokrin L hücrelerinden salgılanan ve kan şekerinin düzenlenmesinde görevli bir peptiddir. ?Glucagon like peptide-2?
TAHSİN ÖZENMİŞ
core  

GLP‐1 Receptor Agonism Exacerbates Activity‐Based Anorexia in Mice

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists reduce food intake and body weight, suggesting they should be avoided in anorexia nervosa. However, preclinical evidence that these drugs reduce activity and reward‐seeking behavior raises the possibility that they might attenuate the compulsive‐like hyperactivity central to ABA ...
Amit Thakar, Travis E. Brown, Shane T. Hentges   +2 more
wiley   +1 more source

Exploring Perspectives on Ozempic: A Netnographic Qualitative Evaluation of the Pro‐Eating Disorder Community on X (Formerly Twitter)

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Eating disorders (EDs) are complex conditions with medical and psychosocial implications. Social media (SM) exposure has been associated with increased body image concerns and maladaptive eating behaviors. Pro‐eating disorder (pro‐ED) communities exist across SM platforms and often perpetuate ED‐related identities and behaviors.
Daisy Sun, Tovah Yanover, Helena Katona, Jennifer Couturier   +3 more
wiley   +1 more source

Empirically Defining “Recurrent” Inappropriate Compensatory Behaviors: Differentiating Binge Eating Disorder From Bulimia Nervosa‐Spectrum Disorders

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective For multiple disorders, DSM‐5‐TR criteria include “recurrent” engagement in behaviors—for example, in the criteria for binge‐eating disorder (BED), “binge eating is not associated with the recurrent use of inappropriate compensatory behavior.”—without operationalizing how frequently a behavior needs to occur to be considered ...
Sophie R. Abber, Dan V. Blalock, Renee D. Rienecke, Philip S. Mehler, Alan Duffy, Jamie Manwaring, Maryrose Bauschka, Kimberly Anderson, Harry A. Brandt, Craig Johnson, Timothy Brewerton, Thomas E. Joiner, Lauren N. Forrest   +12 more
wiley   +1 more source

Preoperative fasting for patients who take GLP-1 receptor agonists: should we Sip Til Send?

Advances in Perioperative Care
In recent years, concerns have arisen regarding the perioperative use of glucagon-like peptide-1 receptor agonist medications and a possible association with increased risk of pulmonary aspiration. The evidence in this setting remains limited.
Louisa Frances Lowes
doaj   +2 more sources

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source

Obesity and hypertension in type 2 diabetes: exploring central and peripheral effects of glucagon-like peptide-1 receptor signalling

Glucagon-like peptide 1 is a hormone involved in the regulation of glucose. Glucose-dependent activation of brain GLP-1R stimulates GLP-1 secretion from the L-cells of the intestine in response to ingested nutrients and it enters the blood stream to ...
Robinson, Louise E.
core